Media stories about Baxter International (NYSE:BAX) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Baxter International earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 46.1588550780914 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Baxter CEO Sees New Products, Expansion Driving Growth (finance.yahoo.com)
- Baxter International (BAX) Given New $83.00 Price Target at Bank of America (americanbankingnews.com)
- Baxter bullish on growth strategy, ups earnings guidance (seekingalpha.com)
- What is Clear choice Buy, Sell or Hold? Baxter International Inc. (BAX) (nysestocks.review)
- Still Listen to Stock Analysts?: Baxter International Inc. (BAX) (nasdaqplace.com)
Baxter International traded down $0.38, hitting $71.72, during trading on Tuesday, according to Marketbeat Ratings. 2,515,700 shares of the company traded hands, compared to its average volume of 3,175,828. The stock has a market capitalization of $37.81 billion, a price-to-earnings ratio of 28.92, a PEG ratio of 1.82 and a beta of 0.81. Baxter International has a 1 year low of $56.82 and a 1 year high of $72.58. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.03 and a current ratio of 2.63.
Baxter International (NYSE:BAX) last posted its earnings results on Thursday, April 26th. The medical instruments supplier reported $0.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.08. The company had revenue of $2.68 billion during the quarter, compared to analysts’ expectations of $2.62 billion. Baxter International had a net margin of 7.75% and a return on equity of 15.70%. Baxter International’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period last year, the company posted $0.58 earnings per share. equities research analysts forecast that Baxter International will post 2.89 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, July 2nd. Investors of record on Friday, June 1st will be paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 1.06%. This is a boost from Baxter International’s previous quarterly dividend of $0.16. The ex-dividend date of this dividend is Thursday, May 31st. Baxter International’s dividend payout ratio (DPR) is presently 25.81%.
Baxter International declared that its board has authorized a stock buyback plan on Tuesday, February 20th that authorizes the company to buyback $1.50 billion in shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.
A number of research analysts recently weighed in on BAX shares. Bank of America increased their price objective on shares of Baxter International from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Tuesday. Zacks Investment Research downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Wednesday, May 16th. Piper Jaffray Companies started coverage on shares of Baxter International in a research report on Thursday, May 17th. They set an “overweight” rating and a $77.00 price objective on the stock. Stifel Nicolaus increased their price target on shares of Baxter International from $71.00 to $72.00 and gave the stock a “hold” rating in a research report on Monday, April 30th. Finally, Citigroup increased their price target on shares of Baxter International from $70.00 to $72.00 and gave the stock a “neutral” rating in a research report on Monday, April 30th. Six research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $73.13.
In other Baxter International news, Director James R. Gavin III sold 18,750 shares of Baxter International stock in a transaction on Wednesday, March 28th. The shares were sold at an average price of $64.56, for a total value of $1,210,500.00. Following the completion of the transaction, the director now directly owns 36,398 shares of the company’s stock, valued at approximately $2,349,854.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brik V. Eyre sold 20,000 shares of Baxter International stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $70.57, for a total transaction of $1,411,400.00. Following the completion of the transaction, the senior vice president now directly owns 85,115 shares of the company’s stock, valued at $6,006,565.55. The disclosure for this sale can be found here. Insiders have sold 47,500 shares of company stock valued at $3,194,912 over the last ninety days. 0.07% of the stock is currently owned by corporate insiders.
About Baxter International
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.